SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1274)3/12/1998 2:12:00 PM
From: Rudy Saucillo  Read Replies (2) | Respond to of 2173
 
Thanks, D.Right. I agree AMLN has made improvements to the protocols of ongoing trials to isolate the effect of pramlintide.

This week's issue of BioCentury has an interesting lead article on projected markets for AMLN and ERGO. To be fair, they cite several clinicians who are advocates of pramlintide for use in both Type I and Type II. It's informative reading.

Rudy


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News